Flexible administration for immediate reversal
- Hang vials and administer as 2 consecutive infusions
- Inject both vials consecutively via syringe
PRAXBIND treatment can be used in conjunction with standard supportive measures, which should be considered as medically appropriate.
Patients treated with Pradaxa® (dabigatran etexilate) therapy have underlying diseases that predispose them to thromboembolic events. Reversing PRADAXA therapy exposes patients to the thrombotic risk of their underlying disease. To reduce this risk, resumption of anticoagulant therapy should be considered as soon as medically appropriate.
PRAXBIND is a specific reversal agent for PRADAXA, with no impact on the effect of other anticoagulant or antithrombotic therapies.
PRADAXA can be re-initiated after 24 hours following PRAXBIND administration.